Dr. Meghan Sise is the Director of Onconephrology at Massachusetts General Hospital and an Associate Professor of Medicine at Harvard Medical School, Boston. She is a graduate of the University of Notre Dame, South Bend, IN, and Columbia University College of Physicians and Surgeons, New York, NY. Her research program focuses on improving the prevention, detection, and treatment of kidney injury that results from anticancer therapies.

DISCLOSURES

Consultant/Advisory Board

Medibeacon; Otsuka; Relay Tx; Merida Bioscience; Biogen; Novartis; Vera; Alpine Immune Science

Speaker's Bureau

Curio; TD Cowen; Medintelligence/Reach MD

Grant/Research Support

Merck Sharp & Dohme LLC; Gilead Sciences, Inc.; AstraZeneca AB; Amgen, Inc.; Genentech, Inc.; Trustees of Columbia University in the City of New York; Syneos Health, LLC; Novartis Pharmaceuticals Corporation; Cabaletta Bio, Inc.

Editorial Boards

Kidney International Reports; American Journal of Kidney Diseases

Leadership Positions in Professional Societies

American Society of Nephrology; National Kidney Foundation

Meghan E. Sise, M.D., M.S.

DISCLOSURES

MORE FROM THE AUTHOR